Outlook TherapeuticsOTLK -6.55%19 EBIT per Share is $-1.25 as of Mar. 2026. GuruFocus rates OTLK with a GF Score™ of 19/100. The stock has 6 warning signs investors should review. Among 1,173 Biotechnology companies, Outlook Therapeutics ranks better than 70.25% on this metric.
Outlook Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.17.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.25.
During the past 3 years, the average EBIT per Share Growth Rate was 31.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 25.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 45.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Outlook Therapeutics's EBIT per Share or its related term are showing as below:
OTLK'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -19.3 Med: 37.7 Max: 65.3
Current: 31.3
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Outlook Therapeutics was 65.30% per year. The lowest was -19.30% per year. And the median was 37.70% per year.
OTLK's 3-Year EBIT Growth Rate is ranked better than 70.25% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs OTLK: 31.30
Outlook Therapeutics (NAS:OTLK) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Outlook Therapeutics EBIT per Share Related Terms
Outlook Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Outlook Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.25
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Outlook Therapeutics (OTLK) has a EBIT per Share of $-1.25 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Outlook Therapeutics and its competitors. According to the industry distribution chart, Outlook Therapeutics ranks #349 out of 1173 companies in the Biotechnology industry, placing it in the top 29.8%.
Is Outlook Therapeutics' EBIT per Share too high?
Outlook Therapeutics' current EBIT per Share is $-1.25. Based on the distribution chart, Outlook Therapeutics ranks #349 out of 1173 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Outlook Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' EBIT per Share compare to FULC and OBIO?
According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #349 out of 1173 companies for EBIT per Share. This puts Outlook Therapeutics in the upper half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Outlook Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Outlook Therapeutics's current EBIT per Share is $-1.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current EBIT per Share of $-1.25. The current EBIT per Share is $-1.25. Outlook Therapeutics' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current EBIT per Share is $-1.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
19GF Score
Get the complete analysis for OTLK
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLK has been successfully added to your 
